Ku, G. Y., O'Reilly, E. M., Saltz, L. B., Schrag, D., Maki, R. G., Kelsen, D. P., Ilson, D. H. (May 2009) Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. Cancer Invest, 27 (4). pp. 402-6. ISSN 1532-4192 (Electronic)0735-7907 (Linking)
Abstract
PURPOSE: We performed a phase I study of 5-fluorouracil (5-FU), cisplatin and irinotecan. METHODS: Twenty-nine patients received cisplatin 25 mg/m(2) and bolus 5-FU 425 mg/m(2), along with irinotecan at 40, 50, and 65 mg/m(2) weekly for 4 out of 6 weeks. RESULTS: The maximum tolerated dose (MTD) for untreated patients was irinotecan 65 mg/m(2) while the MTD for previously treated patients was irinotecan 40 mg/m(2). Neutropenia and diarrhea were the major dose-limiting toxicities. Antitumor activity was noted in gastric, esophageal and pancreatic cancers. CONCLUSION: Because of the toxicity profile, combinations with continuous infusion 5-FU or capecitabine should be explored.
| Item Type: | Paper |
|---|---|
| Uncontrolled Keywords: | Adult Aged Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use Camptothecin/administration & dosage/analogs & derivatives Cisplatin/administration & dosage Diarrhea/chemically induced Digestive System Neoplasms/*drug therapy/pathology Disease Progression Drug Administration Schedule Esophageal Neoplasms/drug therapy Female Fluorouracil/administration & dosage Humans Infusions, Intravenous Injections, Intravenous Male Maximum Tolerated Dose Middle Aged Neutropenia/chemically induced Pancreatic Neoplasms/drug therapy Stomach Neoplasms/drug therapy Time Factors Treatment Outcome |
| Subjects: | diseases & disorders > cancer diseases & disorders > cancer > drugs and therapies |
| CSHL Authors: | |
| Communities: | CSHL labs > Maki lab |
| Depositing User: | Matt Covey |
| Date: | May 2009 |
| Date Deposited: | 25 Oct 2016 20:41 |
| Last Modified: | 25 Oct 2016 20:41 |
| Related URLs: | |
| URI: | https://repository.cshl.edu/id/eprint/33700 |
Actions (login required)
 |
Administrator's edit/view item |
